EUVIMEDSkopri EUVIMED
KohortenstudieOpen access · CC BY-NC-ND 4.0

Current treatment of pT1 rectal cancers in Denmark: A retrospective national cohort study

Henry G Smith iD, Nis H Schlesinger, Peter-Martin Krarup iD, Andreas Nordholm-Carstensen

Colorectal Disease · 2024

DOI: 10.1111/codi.17049 ↗

At a glance

Kohortenstudie in Colorectal Disease, 2024. Written by Henry G Smith and 3 co-authors. Institution: Abdominalcenter K, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. Major MEDLINE topics: Rectal Neoplasms, Proctectomy, Neoplasm Staging. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aim

Organ preservation strategies for patients with rectal cancer are increasingly common. In appropriately selected patients, local excision (LE) of pT1 cancers can reduce morbidity without compromising cancer‐related outcomes. However, determining the need for completion surgery after LE can be challenging, and it is unknown if prior LE compromises subsequent total mesorectal excision (TME). The aim of this study is to describe the current management of patients with pT1 rectal cancers.

Method

This is a retrospective national cohort study of the Danish Colorectal Cancer Group database, including patients with newly diagnosed pT1 cancers between 2016 and 2020. Patients were stratified according to treatment into LE alone, completion TME after LE or upfront TME. The treatment and outcomes of these groups were compared.

Results

A total of 1056 patients were included. Initial LE was performed in 715 patients (67.7%), of whom 194 underwent completion TME (27.1%). The remaining 341 patients underwent upfront TME (32.3%). Patients undergoing LE alone were more likely to be male with low rectal cancers and greater comorbidity. No differences in specimen quality or perioperative outcomes were noted between patients undergoing completion or upfront TME. Eighty‐five patients (15.9%) had lymph node metastases (LNM). Pathological risk factors poorly discriminated between patients with and without LNM, with similar rates seen in patients with zero (14.1%), one (12.0%) or two (14.4%) risk factors.

Conclusion

LE is a key component of the treatment of pT1 rectal cancer and does not appear to affect the outcomes of completion TME. Patient selection for completion TME remains a major challenge, with current stratification methods appearing to be inadequate.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsProctectomyNeoplasm StagingHumansDenmarkMaleRetrospective StudiesFemaleAgedMiddle AgedTreatment OutcomeLymphatic MetastasisOrgan Sparing TreatmentsDatabases, FactualRectumAged, 80 and over

Author keywords

local excisionlymph node metastasesrectal cancer

Authors and institutions

  • Abdominalcenter K, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.

ORCID profiles: Henry G Smith, Peter-Martin Krarup

Cite

APA

Smith, H. G., Schlesinger, N. H., Krarup, P. M., & Nordholm-Carstensen, A. (2024). Current treatment of pT1 rectal cancers in Denmark: A retrospective national cohort study. Colorectal Disease. https://doi.org/10.1111/codi.17049

Vancouver

Smith HG, Schlesinger NH, Krarup PM, Nordholm-Carstensen A. Current treatment of pT1 rectal cancers in Denmark: A retrospective national cohort study. Colorectal Disease. 2024. doi:10.1111/codi.17049

BibTeX
@article{Smith2024,
  author = {Smith, Henry G and Schlesinger, Nis H and Krarup, Peter-Martin and Nordholm-Carstensen, Andreas},
  title = {Current treatment of pT1 rectal cancers in Denmark: A retrospective national cohort study},
  journal = {Colorectal Disease},
  year = {2024},
  doi = {10.1111/codi.17049}
}
Start for free →